DAHANCA 20 Palliative Radiotherapy for Head and Neck Cancer

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00400426

Enrollment

100

Registered

2006-11-16

Start date

2006-11-30

Completion date

2012-06-30

Last updated

2013-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Neoplasms, Neoplasms, Second Primary, Recurrence

Keywords

Palliative radiotherapy, Recurrent, Head and neck Neoplasm, Quality of life

Brief summary

Palliative radiotherapy for head and neck cancer is widely used but the effect and side effects are largely unknown. We will study the effect of short hypofractionated palliative radiotherapy (20 Gy in 4 fractions) on symptom intensity and -frequency as weel as side effects

Interventions

PROCEDURERadiotherapy

20 Gy in 4 fx

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Incurable primary or second primary head and neck cancer * Speaks and reads Danish * Capable of filling out questionnaires for at leas two months after radiotherapy * Age\>=18 years * Expected survival\> 3months

Design outcomes

Primary

Measure	Time frame
Frequency and intensity of symptoms before and after radiotherapy (EORTC C30 and H&N35 questionnaires and CTC AE 3.0 toxicity scores)	11 mths

Secondary

Measure	Time frame
Survival	11 mths
Side effects	2 mths
Other treatments	11 mths

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026